ADORA2A and Parkinson disease: To tackle this question, we resorted to an animal model based on the continuous infusion of MPP+ directly in the lateral ventricles lining the striatum [34] to trigger a slowly evolving PD-like neurodegeneration, where there is a temporal separation between the initial striatal synaptotoxicity and the delayed overt degeneration of DA cell bodies, with the aim of comparing the impact of A2AR antagonists on these two processes occurring in different phases of PD.